Quick Takeaways
- NEWTON (PTC) Ltd filed SCHEDULE 13G/A for LYELL IMMUNOPHARMA, INC. Common Stock, $0.0001 par value per share (LYEL).
- Disclosed ownership: 3.9%.
- Date of event: 30 Sep 2025.
NEWTON (PTC) Ltd - 30 Sep 2025 SCHEDULE 13G/A Report for LYELL IMMUNOPHARMA, INC. Common Stock, $0.0001 par value per share (LYEL)
- Filing Manager
- NEWTON (PTC) Ltd
- Reporting Manager
- Newton (PTC) Limited
- Symbol
- LYEL
- Shares outstanding
- 19,203,511 shares
- Disclosed Ownership
- 754,698 shares
- Ownership
- 3.9%
- Form type
- SCHEDULE 13G/A
- Filing time
- 12 Nov 2025, 16:57:35 UTC
- Date of event
- 30 Sep 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"NEWTON (PTC) Ltd disclosed 3.9% ownership in LYELL IMMUNOPHARMA, INC. Common Stock, $0.0001 par value per share (LYEL) on 30 Sep 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 12 Nov 2025, 16:57.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (4)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Newton (PTC) Limited | 3.9% | 754,698 | 754,698 | 0 | /s/ David Muir | David Muir / President | |
| Orland Properties Limited | 3.9% | 754,698 | 754,698 | 0 | //s/ David Muir | David Muir / President | |
| Gemini GP Limited | 3.9% | 754,698 | 754,698 | 0 | /s/ David Muir | David Muir / President | |
| Gemini Investments, L.P. | 3.9% | 754,698 | 754,698 | 0 | By: Gemini GP Limited, its General Partner /s/ David Muir | David Muir / President |